

Aus dem Max-Planck-Institut für molekulare Genetik

Geschäftsführender Direktor: Prof. Dr. rer. nat. Martin Vingron
Abteilungsleiter: Prof. Dr. med. Hans-Hilger Ropers
Arbeitsgruppe: Dr. rer. nat. Vera Kalscheuer

**Identification and characterisation of genes
involved in cognitive function**

Inaugural-Dissertation
zur Erlangung des Grades Doctor rerum medicarum
der Charité-Universitätsmedizin Berlin

vorgelegt von: Sarah Althea Shoichet
aus: Mission, British Columbia, Canada

Referent: Prof. Dr. med. Burghardt Wittig

Korreferent: Prof. Dr. med. Hans-Hilger Ropers

Gedruckt mit Genehmigung der Charité-Universitätsmedizin Berlin
Campus Benjamin Franklin

Promotionsdatum: 03.09.2004

In this dissertation, words believed to constitute trademarks have been designated as such. However, neither the presence nor absence of such designation should be regarded as affecting the legal status of any trademark.

TABLE OF CONTENTS

1. INTRODUCTION.....	4
1.1 Identifying genetic causes of mental retardation: historical overview.....	4
1.2 Mechanisms by which gene defects cause MR.....	8
1.2.1 Chromatin remodelling and MR.....	9
1.2.2 GTP-binding proteins, signal transduction, and MR.....	12
1.3 Utilising chromosome abnormalities for identification of candidate MR genes.....	16
1.4 Aim of the study.....	17
2. MATERIALS AND METHODS.....	18
2.1 Materials.....	18
2.1.1 Chemicals.....	18
2.1.2 Solutions and media.....	19
2.1.3 Enzymes.....	21
2.1.4 Kits.....	21
2.1.5 Vectors.....	22
2.1.6 Cell culture reagents	22
2.1.7 Antibodies.....	22
2.1.8 Human genomic material.....	23
2.1.9 Bacteria.....	23
2.1.10 Mammalian cell lines.....	23
2.1.11 Translocation patients, XLMR families, and controls.....	23
2.1.12 Online resources for clone mapping and alignments.....	24
2.2 Methods.....	25
2.2.1 DNA isolation.....	25
2.2.2 RNA isolation.....	25
2.2.3 Fluorescence <i>in situ</i> hybridisation (FISH).....	25
2.2.4 Preparation of DNA probes for hybridisation.....	26
2.2.5 RT-PCR experiments.....	27
2.2.6 Isotope-labelling of probes for hybridisations.....	28
2.2.7 Library screening.....	28
2.2.8 Southern blot hybridisations.....	29
2.2.9 Northern blot hybridisations.....	29
2.2.10 Breakpoint cloning (Patient 3).....	30
2.2.11 Mutation screening of <i>ZNF41</i> by denaturing high performance liquid chromatography (DHPLC).....	31
2.2.12 Cell fractionation and western blotting.....	33
2.2.13 Recombinant DNA techniques.....	33
2.2.14 Cell culture conditions and transfection experiments.....	34
2.2.15 Immunofluorescence.....	35

3. RESULTS.....	36
3.1 Clinical and molecular studies in patients with disease-associated X;autosome translocations: the search for candidate MRX genes.....	36
3.1.1 Patient 1 with translocation t(X;7)(q22;p22).....	36
3.1.2 Patient 2 with translocation t(X;15)(q13;p11).....	39
3.1.3 Patient 3 with translocation t(X;7)(p11.3;q11.21).....	42
3.2 Further investigations into the relationship between ZNF41 and MR.....	46
3.2.1 The X-chromosomal ZNF41 gene is disrupted near the 5' end.....	46
3.2.2 Full-length ZNF41 transcripts are absent in the patient cell line.....	47
3.2.3 ZNF41 is expressed in multiple tissues including brain.....	48
3.2.4 Identification and studies on two novel, potentially disease-causing ZNF41 sequence alterations in a panel of patients with XLMR.....	49
3.2.5 Studies on family P13 with proline to leucine mutation.....	50
3.2.6 Studies on documented ZNF41 transcripts in family P42 with splice-site mutation.....	52
3.2.7 Identification of a novel ZNF41 splice variant also affected in family P42..	54
3.2.8 Expression analysis of ZNF41 variants affected by the splice site mutation in family P42.....	55
3.3 Clinical and molecular studies in patients with disease-associated autosome translocations: the search for autosomal candidate MR genes.....	57
3.3.1 Patient 4 with translocation t(2;14)(p22;q13).....	57
3.3.2 Patient 5 with translocation t(Y;4)(q11.2;q21).....	61
3.4 Further studies on Patient 5 and the role of JNK3 in MR.....	65
3.4.1 The breakpoint disrupts JNK3 α isoforms after amino acid 267.....	65
3.4.2 Truncated JNK3 lacks kinase domains X and XI and is expressed in the patient lymphoblastoid cell line.....	66
3.4.3 Ectopic expression of truncated JNK3 differs from that of the wild type....	68
4. DISCUSSION.....	70
4.1 Selection of X-chromosomal candidate genes for further studies.....	70
4.1.1 Patient 1 with translocation t(X;7)(q22;p22).....	70
4.1.2 Patient 2 with translocation t(X;15)(q13;p11).....	71
4.1.3 Patient 3 with translocation t(X;7)(p11.3;q11.21).....	72
4.2 Understanding the role of ZNF41 in cognition.....	73
4.2.1 ZNF41 alterations are associated with cognitive dysfunction.....	73
4.2.2 Zinc finger genes, transcriptional repression and MR.....	74
4.2.3 KRAB/ZFPs and evolution: ZNF41 is a candidate gene for higher cognitive functions.....	75
4.3 Selection of autosomal candidate genes for further studies.....	77
4.3.1 Patient 4 with translocation t(2;14)(p22;q13).....	77

4.3.2	Patient 5 with translocation t(Y;4)(q11.2;q21).....	78
4.4	Understanding the role of a truncated JNK3 in MR.....	80
4.4.1	A truncated JNK3 likely interferes with normal JNK3 function in neurons.....	80
4.4.2	Links between Rho-GTPase signalling, neurite outgrowth, and JNKs.....	80
4.4.3	JNKs within the context of Rho-GTPase-mediated signalling and MR.....	82
4.4.4	Proposed model for a mutant JNK3 in the aetiology of MR.....	87
5.	SUMMARY.....	89
6.	ZUSAMMENFASSUNG.....	91
7.	OUTLOOK.....	93
	REFERENCES.....	95
	ABBREVIATIONS.....	105
	LIST OF FIGURES.....	108
	LIST OF TABLES.....	109
	ACKNOWLEDGEMENTS.....	110
	CURRICULUM VITAE.....	111
	PUBLICATIONS.....	113